Cargando…
Proteomic Analysis of Ovarian Cancer Proximal Fluids: Validation of Elevated Peroxiredoxin 1 in Patient Peripheral Circulation
BACKGROUND: Epithelial ovarian cancer (EOC) is the deadliest gynecologic malignancy in the United States. Unfortunately, a validated protein biomarker-screening test to detect early stage disease from peripheral blood has not yet been developed. The present investigation assesses the ability to iden...
Autores principales: | Hoskins, Ebony R., Hood, Brian L., Sun, Mai, Krivak, Thomas C., Edwards, Robert P., Conrads, Thomas P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3184097/ https://www.ncbi.nlm.nih.gov/pubmed/21980378 http://dx.doi.org/10.1371/journal.pone.0025056 |
Ejemplares similares
-
Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes
por: Teng, P-N, et al.
Publicado: (2014) -
Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues
por: Penick, Emily R., et al.
Publicado: (2022) -
The prognostic values of the peroxiredoxins family in ovarian cancer
por: Li, Saisai, et al.
Publicado: (2018) -
Proteomic Analysis of Matched Formalin-Fixed, Paraffin-Embedded Specimens in Patients with Advanced Serous Ovarian Carcinoma
por: Smith, Ashlee L., et al.
Publicado: (2013) -
Diagnostic Proteomics: Serum Proteomic Patterns for the Detection of Early Stage Cancers
por: Yu, Li-Rong, et al.
Publicado: (2004)